Sales growth driven by COPD therapy Spiriva and the anticoagulant Pradaxa
Expected to be a huge blockbuster, LCZ696 has become the first non-cancer therapy likely to be included in the Early Access to Medicines Scheme.
Licensing deal worth up to $555 million
Miconazole (for athlete's foot) and clobetasol - may activate stem cells to stimulate myelin-producing cells and repair white matter, damaged in MS. Very early-stage though
Such a combination "is without sound industrial logic or cultural fit"
Agency says results should be publicly reported within 12 months of a trial’s end, whether a success or failure
Phase III trial stopped early for already-approved therapy as progression-free survival primary endpoint is met
First new treatment for CHF to be approved in the USA in nearly a decade
Green lights for Ariad leukaemia therapy Iclusig, Bayer GIST treatment Stivarga and BI's Vargatef for lung cancer
Will enable doctors and researchers to draw on real-time insights from data 'at a scale never before possible'
Field force concerned about Patient First programme and GSK's new incentive scheme
Exp. Medical Reps and trainees. KAMs; eDetailing Reps Nationwide Opportunities
Click here to apply now!
New Sales Role!
Click here to apply!
Nurse Advisor Roles
Click here to apply now
Find your next position today!
Click here to apply
Contracts and Pricing Manager
No running polls, please check backsoon.
Increase your knowledge. Browse the Pf Archive.
Read Pf now
Looking to make a move? Find your next job here.
click here to createan account
Need career advice? Visit our Career Centre.